Patents Assigned to BioCrine AB
  • Methods for monitoring physiological status of a body organ
    Patent number: 11519902
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: December 6, 2022
    Assignee: Biocrine AB
    Inventor: Per-Olof Berggren
  • Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
    Patent number: 10695425
    Abstract: Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 30, 2020
    Assignee: Biocrine AB
    Inventor: Per-Olof Berggren
  • Non-invasive in vivo imaging and methods for treating diabetes
    Patent number: 10493108
    Abstract: The present invention provides novel drug discovery platforms and methods for treating diabetes.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: December 3, 2019
    Assignee: BioCrine AB
    Inventors: Per-Olof Berggren, Alejandro Caicedo
  • Methods for monitoring physiological status of a body organ
    Patent number: 10338060
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: July 2, 2019
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Methods for monitoring physiological status of a body organ
    Patent number: 10228364
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: March 12, 2019
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Methods for treating and/or limiting development of diabetes
    Patent number: 10226530
    Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 12, 2019
    Assignee: BioCrine AB
    Inventors: Per Olof Berggren, Shao-Nian Yang
  • Non-invasive in vivo imaging and methods for treating type I diabetes
    Patent number: 10207012
    Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: February 19, 2019
    Assignee: Biocrine AB
    Inventors: Per-Olof Berggren, Alejandro Caicedo
  • ApoIII and the treatment and diagnosis of diabetes
    Patent number: 10060935
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic ? cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic ? cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: August 28, 2018
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
    Patent number: 9968675
    Abstract: Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 15, 2018
    Assignee: BioCrine AB
    Inventor: Per Olof Berggren
  • Methods for treating and/or limiting development of diabetes
    Patent number: 9744232
    Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: August 29, 2017
    Assignee: BioCrine AB
    Inventors: Per Olof Berggren, Shao-Nian Yang
  • Methods for monitoring physiological status of a body organ
    Patent number: 9702867
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 11, 2017
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis
    Patent number: 9700617
    Abstract: Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: July 11, 2017
    Assignee: BioCrine AB
    Inventor: Per Olof Berggren
  • Methods for monitoring physiological status of a body organ
    Patent number: 9462973
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: October 11, 2016
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Non-invasive in vivo imaging and methods for treating type I diabetes
    Patent number: 9463205
    Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: October 11, 2016
    Assignee: BioCrine AB
    Inventors: Per-Olof Berggren, Alejandro Caicedo
  • Methods for treating and/or limiting development of diabetes
    Patent number: 9353183
    Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: May 31, 2016
    Assignee: BioCrine AB
    Inventors: Per Olof Berggren, Shao-Nian Yang
  • ApoIII and the treatment and diagnosis of diabetes
    Patent number: 9169484
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic ? cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic ? cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: October 27, 2015
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Methods for treating and/or limiting development of diabetes
    Patent number: 9068973
    Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: June 30, 2015
    Assignee: BioCrine AB
    Inventors: Per Olof Berggren, Shao-Nian Yang
  • Methods for treating and/or limiting development of diabetes
    Patent number: 9068971
    Abstract: The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 30, 2015
    Assignee: BioCrine AB
    Inventors: Per Olof Berggren, Shao-Nian Yang
  • Methods for identifying compounds for treating type 1 diabetes
    Patent number: 9062306
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes by identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: June 23, 2015
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • ApoIII and the Treatment and Diagnosis of Diabetes
    Publication number: 20140220039
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic ? cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic ? cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.
    Type: Application
    Filed: March 21, 2014
    Publication date: August 7, 2014
    Applicant: BioCrine AB
    Inventor: Per-Olof BERGGREN